Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-12T06:08:58.212Z Has data issue: false hasContentIssue false

Adjunctive citalopram is effective on hallucinations and depersonalization symptoms: a case report

Published online by Cambridge University Press:  16 April 2020

Vittorio Di Michele*
Affiliation:
Department of Mental Health, Pescara, Italy
*
*Corresponding author. E-mail address: vdimich@tin.it

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The treatment of depressive symptoms in patients affected by schizophrenia is often a concern for clinicians [2] due to potential interaction, in terms of safety and efficacy. Citalopram seems to be a safe SSRI as adjunctive treatment to Olanzapine because of the lack of interactions. We report a serendipitous finding showing that the adjunction of Citalopram to Olanzapine, led to disappearence of residual hallucinations and depersonalization symptoms in a few weeks.

Mr A is a 27-year-old male, living in the community, with a 4-year history of schizophrenia,. He was treated with low doses of Olanzapine (10 mg/daily) since 2000 because of an intolerance to dose increments (weight gain and mydriasis).The persistence of sporadic hallucinations (commenting voices) and depersonalization symptoms (when he walked alone he felt his self leaving the body) was well tolerated by the patient. The social functioning was satisfactory: he had a protected job and was involved in a comprehensive rehabilitation programme.

Type
Letter to the editor
Copyright
Copyright © 2004 European Psychiatric Association

References

Liotti, MMayberg, HSMcGinnis, SBranna, SLJerabek, P.Unmasking disease specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry 2002;159:1830–40.CrossRefGoogle ScholarPubMed
Siris, SG.Depression in schizophrenia: perspective in the era of atypical antipsychotic agents. Am J Psychiatry 2000;157:1379–89.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.